MiNK Therapeutics Inc. has announced its financial results for the first quarter of 2025. The company reported a net loss of $2.8 million for this period, which marks an improvement from the $3.8 million net loss recorded in the first quarter of 2024. The net loss per share was $0.70 compared to $1.10 in the same period last year. MiNK ended the quarter with a cash balance of $3.2 million, and cash used in operations was $1.3 million, down from $2.5 million in the corresponding period of 2024. In its business operations, MiNK highlighted clinical progress with complete response data in testicular cancer, ongoing enrollment in a Phase 2 gastric trial, and new data emerging in PD-1-resistant tumors. Additionally, MiNK is poised to receive probable funding from NIAID by June 2025 to support its allogeneic iNKT program in GvHD, signaling recognition of its leadership in inflammation and immune modulation. These developments are seen as expansion opportunities within MiNK's core verticals, including solid tumors, inflammatory disease, and next-generation engineered cell therapies.